Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation
Xiaobin Luo, … , Baofeng Yang, Stanley Nattel
Xiaobin Luo, … , Baofeng Yang, Stanley Nattel
Published April 1, 2013
Citation Information: J Clin Invest. 2013;123(5):1939-1951. https://doi.org/10.1172/JCI62185.
View: Text | PDF
Research Article Cardiology

MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation

  • Text
  • PDF
Abstract

Atrial fibrillation (AF) is a highly prevalent arrhythmia with pronounced morbidity and mortality. Inward-rectifier K+ current (IK1) is believed to be an important regulator of reentrant-spiral dynamics and a major component of AF-related electrical remodeling. MicroRNA-26 (miR-26) is predicted to target the gene encoding KIR2.1, KCNJ2. We found that miR-26 was downregulated in atrial samples from AF animals and patients and this downregulation was accompanied by upregulation of IK1/KIR2.1 protein. miR-26 overexpression suppressed expression of KCNJ2/KIR2.1. In contrast, miR-26 knockdown, inhibition, or binding-site mutation enhanced KCNJ2/KIR2.1 expression, establishing KCNJ2 as a miR-26 target. Knockdown of endogenous miR-26 promoted AF in mice, whereas adenovirus-mediated expression of miR-26 reduced AF vulnerability. Kcnj2-specific miR-masks eliminated miR-26–mediated reductions in Kcnj2, abolishing miR-26’s protective effects, while coinjection of a Kcnj2-specific miR-mimic prevented miR-26 knockdown-associated AF in mice. Nuclear factor of activated T cells (NFAT), a known actor in AF-associated remodeling, was found to negatively regulate miR-26 transcription. Our results demonstrate that miR-26 controls the expression of KCNJ2 and suggest that this downregulation may promote AF.

Authors

Xiaobin Luo, Zhenwei Pan, Hongli Shan, Jiening Xiao, Xuelin Sun, Ning Wang, Huixian Lin, Ling Xiao, Ange Maguy, Xiao-Yan Qi, Yue Li, Xu Gao, Deli Dong, Yong Zhang, Yunlong Bai, Jing Ai, Lihua Sun, Hang Lu, Xiao-Yan Luo, Zhiguo Wang, Yanjie Lu, Baofeng Yang, Stanley Nattel

×

Figure 4

Verification of the specificity of miR-26/KCNJ2/Kir2.1 in the control of AF.

Options: View larger image (or click on image) Download as PowerPoint
Verification of the specificity of miR-26/KCNJ2/Kir2.1 in the control of...
(A) Inhibitory effect of LNA–miR-mimic on induction (left) and maintenance in inducible animals (right) of AF induced in mice also treated with LNA–anti–miR-26a. MM LNA–miR-mimic, mismatched miR-mimic (negative control). Number inducible/total used is indicated by n/N values within brackets. *P < 0.05, ***P < 0.001 vs. WT; ϕϕP < 0.01, ϕϕϕP < 0.001 vs. LNA–anti–miR-26a alone; §P < 0.05 vs. LNA–anti–miR-26a + LNA–miR-mimic. (B) Western blot verifying ability of miR-mimic to knock down Kir2.1. **P < 0.01 vs. WT; ϕϕP < 0.01 vs. LNA–anti–miR-26a alone; §§P < 0.01 vs. LNA–anti–miR-26a + LNA–miR-mimic; n = 6 for each group. (C) LNA–miR-mask abolishes the protective effect of adv–miR-26a against AF induction (left) and maintenance (right). +LNA–miR-mask,mice injected with LNA–miR-mask (5 mg/kg/d daily for 3 days before injection of adv–miR-26a); LNA–miR-mask, mice injected with LNA–miR-mask alone; MM miR-mask, mismatched miR-mask (negative control). *P < 0.05 vs. WT; ϕP < 0.05, ϕϕP < 0.01 vs. adv–miR-26a alone; §§P < 0.01 vs. adv–miR-26a + LNA–miR-mask. (D) Western blot verifying ability of miR-mask to protect against Kir2.1 knockdown by adv–miR-26a. ***P < 0.001 vs. WT; ϕϕϕP < 0.001 vs. adv–miR-26a alone; §§§P < 0.001 vs. adv–miR-26a + LNA–miR-mask; n = 6/group. Values are mean ± SEM. Group definitions as in Figure 3. Note: the experiments shown in Figure 3A and Figure 4, A and C, were done contemporaneously. Thus, the same WT group data serve as controls in each case, and the same LNA–anti–miR-26a and adv–miR-26a data are shown in Figure 3 and Figure 4. Related data sets for AF incidence and AF duration are shown separately for clarity in display. However, statistical comparisons were performed between all animals with interventions simultaneously (see Supplemental Figure 6).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts